VIDEO: Osimertinib after chemoradiation may benefit EGFR-mutated advanced NSCLC
Click Here to Manage Email Alerts
Melina Elpi Marmarelis, MD, discussed research on the use of osimertinib versus durvalumab following chemoradiation in patients with stage III EGFR-mutated NSCLC.
The study was presented at this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer.
“This is evaluating an off-label use of osimertinib — after chemoradiation — but it’s extrapolated from the data from [the ADAURA trial], where osimertinib is used post-surgical resection,” Marmarelis, medical director of the Penn Mesothelioma Program and an assistant professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania, told Healio.
She explained that the researchers found that osimertinib (Tagrisso, AstraZeneca) after chemoradiation had superior DFS compared to durvalumab (Imfinzi, AstraZeneca) and that that OS did not differ between the two groups.
Marmarelis noted that researchers observed a higher rate of pneumonitis among patients who received durvalumab.
“Ultimately, I think this confirms that patients with classical, sensitizing EGFR mutations really shouldn’t receive durvalumab after chemoradiation because of lack of benefit, but also because of potential toxicity if they receive osimertinib after durvalumab,” she said.
Collapse
Nassar A, et al. MA16.11. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer; Sept. 9-12, 2023; Singapore.
Read more about
Click Here to Manage Email Alerts